# US 2019/0376140 A1 · Biomarkers for premature birth

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376140 A1
- Document ID: US20190376140A1
- Status: Published application
- Kind: A1
- Application number: 16/547,229
- Filed: 2019-08-21
- Published: 2019-12-12
- Earliest claimed: 2013-07-24
- Assignees: The Chinese University of Hong Kong
- Applicants: The Chinese University of Hong Kong
- Inventors: Stephen Siu-Chung CHIM; Chee Yin Cheung; Cheung Cheung; Tak Yeung Leung; Wing Shan Lee
- Web page: https://patentgrep.com/patent/US20190376140A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/06: Antiabortive agents; Labour repressants
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- C12Q 2600/166: Oligonucleotides used as internal standards, controls or normalisation probes
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a method for determining increased risk of premature birth in a pregnant woman by detecting altered expression level of one or more marker genes in the woman's blood. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for preventing or reducing the likelihood of premature birth.

## Claims

### Claim 1

A method for determining risk of premature birth, comprising the steps of:
(a) measuring mRNA level of a marker in a blood sample taken from a pregnant woman, wherein the marker is selected from the group consisting of the genes in Table 2, CD16A, and CD62L; and
(b) comparing the mRNA level obtained in step (a) with a standard control,
wherein an increase or decrease in the mRNA level when compared with the standard control indicates the woman having increased risk of premature birth.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sample is whole blood.

### Claim 3 (depends on 1)

The method of claim 1, wherein the sample is isolated blood cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein the sample is plasma.

### Claim 5 (depends on 1)

The method of claim 1, wherein the sample is serum.

### Claim 6 (depends on 1)

The method of claim 1, wherein the marker is B3GNT5, CD16A, or CD62L, and wherein an increase in the mRNA level when compared with the standard control indicates the woman having increased risk of premature birth.

### Claim 7 (depends on 1)

The method of claim 1, wherein the marker is CLC or GBP3, and wherein a decrease in the mRNA level when compared with the standard control indicates the woman having increased risk of premature birth.

### Claim 8 (depends on 1)

The method of claim 1, wherein the mRNA level is normalized over the mRNA level of a reference gene in the same sample prior to step (b).

### Claim 9 (depends on 1)

The method of claim 1, wherein step (a) comprises mass spectrometry or hybridization to a microarray, fluorescence probe, or molecular beacon.

### Claim 10 (depends on 1)

The method of claim 1, wherein step (a) comprises an amplification reaction.

### Claim 11 (depends on 10)

The method of claim 10, wherein the amplification reaction is a polymerase chain reaction (PCR).

### Claim 12 (depends on 11)

The method of claim 11, wherein the PCR is a reverse transcriptase-PCR (RT-PCR).

### Claim 13 (depends on 1)

The method of claim 1, wherein step (a) comprises a polynucleotide hybridization assay utilizing a polynucleotide probe comprising a detectable moiety.

### Claim 14 (depends on 13)

The method of claim 13, wherein the polynucleotide hybridization assay is a Southern Blot analysis, Northern Blot analysis, or an in situ hybridization assay.

### Claim 15 (depends on 1)

The method of claim 1, wherein the mRNA level is normalized over the mRNA level of a reference gene in the same sample prior to step (b).

### Claim 16 (depends on 15)

The method of claim 15, wherein the reference gene is GAPDH.

### Claim 17 (depends on 1)

The method of claim 1, when the woman is indicated as having increased risk of premature birth, further comprising a step of treating the woman for premature birth.

### Claim 18 (depends on 1)

The method of claim 1, wherein the mRNA level of more than one marker genes is measured and compared with their respective standard controls to determine risk of premature birth.

### Claim 19

A kit for determining risk of premature birth, comprising (1) a standard control that provides an average level of a marker gene mRNA; and (2) an agent that specifically and quantitatively identifies the marker gene mRNA, wherein the marker gene is selected from the group consisting of the genes in Table 2, CD16A, and CD62L.

### Claim at position 20

-23. (canceled)

### Claim 24

A method for reducing risk of premature birth in a pregnant woman, comprising administering to the woman an effective amount of (1) an antisense polynucleotide sequence or an siRNA against a marker gene in Table 2, or against CD16A or CD62L; or (2) an expression cassette comprising the cDNA sequence of a marker gene in Table 2 and directing the transcription of the marker gene.

### Claim 25

(canceled)
